{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:56:56Z","timestamp":1793235416499,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clim.2023.109682","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T06:36:07Z","timestamp":1687934167000},"page":"109682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Infliximab for vascular involvement in Beh\u00e7et's syndrome"],"prefix":"10.1016","volume":"253","author":[{"given":"Gulen","family":"Hatemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Beyza","family":"Tukek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem Nihal","family":"Esatoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Ozguler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitki Safa","family":"Taflan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Uygunoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike","family":"Melikoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdal","family":"Ugurlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izzet","family":"Fresko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksel","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekayi","family":"Kutlubay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebahattin","family":"Yurdakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedat","family":"Hamuryudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clim.2023.109682_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2023.109682_bb0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.berh.2016.08.002","article-title":"Behcet\u2019s disease: how to diagnose and treat vascular involvement","volume":"30","author":"Seyahi","year":"2016","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.clim.2023.109682_bb0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00296-019-04283-y","article-title":"Clinical course of abdominal aortic aneurysms in Behcet disease: a retrospective analysis","volume":"39","author":"Sahutoglu","year":"2019","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.clim.2023.109682_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","article-title":"Vascular Behcet syndrome: from pathogenesis to treatment","volume":"19","author":"Bettiol","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2023.109682_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e3182428f49","article-title":"Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature","volume":"91","author":"Geri","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.clim.2023.109682_bb0030","first-page":"808","article-title":"2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.clim.2023.109682_bb0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/rheumatology\/kez352","article-title":"Clinical course of acute deep vein thrombosis of the legs in Behcet\u2019s syndrome","volume":"59","author":"Ozguler","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.clim.2023.109682_bb0040","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.40531","article-title":"Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Behcet\u2019s syndrome: a retrospective study of seventy patients with vascular involvement","volume":"70","author":"Emmi","year":"2018","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2023.109682_bb0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/14656566.2022.2155047","article-title":"Current pharmacological solutions for Behcet\u2019s syndrome","volume":"24","author":"Ozguler","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.clim.2023.109682_bb0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.semarthrit.2015.06.008","article-title":"Pulmonary artery involvement in Behcet\u2019s syndrome: effects of anti-Tnf treatment","volume":"45","author":"Hamuryudan","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.clim.2023.109682_bb0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.autrev.2016.01.003","article-title":"Pulmonary artery aneurysms in Behcet\u2019s disease treated with anti-TNFalpha: a case series and review of the literature","volume":"15","author":"Chan","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2023.109682_bb0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","article-title":"Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet\u2019s disease: a multicenter observational study of 18 patients","volume":"197","author":"Desbois","year":"2018","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2023.109682_bb0065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/1756-185X.13778","article-title":"Efficacy of TNFalpha inhibitors for refractory vascular Behcet\u2019s disease: a multicenter observational study of 27 patients and a review of the literature","volume":"23","author":"Aksoy","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.clim.2023.109682_bb0070","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1708538120927701","article-title":"Infliximab treatment in refractory vascular Behcet\u2019s disease: a single-center experience","volume":"28","author":"Kehribar","year":"2020","journal-title":"Vascular."},{"issue":"4","key":"10.1016\/j.clim.2023.109682_bb0075","first-page":"303","article-title":"Efficacy and safety of anti-tumor necrosis factor alpha monoclonal antibodies in 16 patients with severe\/refractory vasculo Behcet\u2019s disease","volume":"59","author":"Li","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"1","key":"10.1016\/j.clim.2023.109682_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MD.0b013e3182428126","article-title":"Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients","volume":"91","author":"Saadoun","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.clim.2023.109682_bb0085","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.clim.2023.109682_bb0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0037-1604411","article-title":"Outcomes of patients with Behcet\u2019s syndrome after pulmonary endarterectomy","volume":"66","author":"Yildizeli","year":"2018","journal-title":"Thorac. Cardiovasc. Surg."},{"issue":"9","key":"10.1016\/j.clim.2023.109682_bb0095","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10067-006-0530-9","article-title":"Surgical outcomes and risk factors for postoperative complications in patients with Behcet\u2019s disease","volume":"26","author":"Park","year":"2007","journal-title":"Clin. Rheumatol."},{"issue":"9","key":"10.1016\/j.clim.2023.109682_bb0100","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/rheumatology\/kez598","article-title":"Long term follow-up of Behcet\u2019s syndrome patients treated with cyclophosphamide","volume":"59","author":"Gurcan","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.clim.2023.109682_bb0105","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1093\/rheumatology\/keab944","article-title":"Emergence of new manifestations during infliximab treatment in Behcet\u2019s syndrome","volume":"61","author":"Tukek","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2023.109682_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109263","article-title":"Earlier and more aggressive treatment with biologics may prevent relapses and further new organ involvement in Behcet\u2019s disease","volume":"248","author":"Bozkurt","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109682_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109272","article-title":"Difficult-to-treat Behcet syndrome: a therapeutic approach","volume":"249","author":"Yazici","year":"2023","journal-title":"Clin. Immunol."},{"issue":"11","key":"10.1016\/j.clim.2023.109682_bb0120","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/rheumatology\/keu233","article-title":"Vascular involvement in Behcet\u2019s syndrome: a retrospective analysis of associations and the time course","volume":"53","author":"Tascilar","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"44","key":"10.1016\/j.clim.2023.109682_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001899","article-title":"Clinical and ultrasonographic evaluation of lower-extremity vein thrombosis in Behcet syndrome: an observational study","volume":"94","author":"Seyahi","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.clim.2023.109682_bb0130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jvsv.2016.01.003","article-title":"Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular Behcet\u2019s disease","volume":"4","author":"Alibaz-Oner","year":"2016","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"issue":"6","key":"10.1016\/j.clim.2023.109682_bb0135","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jvsv.2021.02.007","article-title":"Predictors for the risk and severity of post-thrombotic syndrome in vascular Behcet\u2019s disease","volume":"9","author":"Aksoy","year":"2021","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"issue":"1","key":"10.1016\/j.clim.2023.109682_bb0140","first-page":"178","article-title":"Leg ulcers in Behcet\u2019s disease","volume":"158","author":"Jung","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"16","key":"10.1016\/j.clim.2023.109682_bb0145","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010515","article-title":"Successful mesenchymal stem cell treatment of leg ulcers complicated by Behcet disease: a case report and literature review","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162300445X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162300445X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T01:03:17Z","timestamp":1725930197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166162300445X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":29,"alternative-id":["S152166162300445X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2023.109682","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab for vascular involvement in Beh\u00e7et's syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2023.109682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109682"}}